Journal of Clinical Pediatrics >
The clinical significance and management strategies of B cell aplasia following CD19 CAR-T cell therapy in pediatric patients
Received date: 2024-06-05
Online published: 2024-07-08
B cell aplasia (BCA) is a common adverse side effect in pediatric patients with B-acute lymphoblastic leukemia (B-ALL) following CD19-chimeric antigen receptor T-cell (CD19 CAR-T) therapy. The duration of BCA has an impact on the immune status and prognosis of patients. A thorough understanding of BCA helps physicians choose treatment plans in a scientific, normative, and reasonable manner, reducing the risk of infection in pediatric leukemia patients after CAR-T treatment and improving their prognosis and quality of life.
Key words： B-acute lymphoblastic leukemia; CD19 CAR-T; B cell aplasia; child
Jun LU . The clinical significance and management strategies of B cell aplasia following CD19 CAR-T cell therapy in pediatric patients[J]. Journal of Clinical Pediatrics, 2024 , 42(7) : 578 -582 . DOI: 10.12372/jcp.2024.24e0577
| [1] | Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia[J]. Haematologica, 2020, 105(11): 2524-2539. |
| [2] | Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 449-459. |
| [3] | Laetsch TW, Maude SL, Rives S, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial[J]. J Clin Oncol, 2023, 41(9): 1664-1669. |
| [4] | Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL[J]. Blood, 2019, 134(26): 2361-2368. |
| [5] | Maria Gabelli, Macarena Oporto-Espuelas, Saskia Burridge, et al. Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy[J]. Blood Adv, 2024, 8(8): 1959-1963. |
| [6] | Levine JE, Grupp SA, Pulsipher MA, et al. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia[J]. J Immunother Cancer, 2021, 9: e002287. |
| [7] | Deyà-Martínez A, Alonso-Saladrigues A, García AP, et al. Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia[J]. Bone Marrow Transplant, 2021, 56(2): 376-386. |
| [8] | Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy[J]. Blood, 2018, 131: 121-130. |
| [9] | Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial[J]. Lancet Oncol, 2019, 20: 31-42. |
| [10] | Otani IM, Lehman HK, Jongco AM, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees[J]. J Allergy Clin Immunol, 2022, 149(5): 1525-1560. |
| [11] | Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 439-448. |
| [12] | Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy[J]. Blood, 2018, 131: 121-130. |
| [13] | Baird JH, Epstein DJ, Tamaresis JS, et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma[J]. Blood Adv, 2021, 5(1): 143-155. |
| [14] | Kambhampati S, Sheng Y, Huang CY, et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy[J]. Blood Adv, 2022, 6(7): 2045-2054. |
| [15] | Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med, 2019, 380(1): 45-56. |
| [16] | Wu X, Cao Z, Chen Z, et al. Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia[J]. Clin Exp Med, 2024, 24(1): 87. |
| [17] | Deyà-Martínez A, Alonso-Saladrigues A, García AP, et al. Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia[J]. Bone Marrow Transplant, 2021, 56(2): 376-386. |
| [18] | Arnold DE, Maude SL, Callahan CA, et al. Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients[J]. Pediatr Blood Cancer, 2020, 67(3): e28092. |
| [19] | Hill JA, Giralt S, Torgerson TR, et al. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy[J]. Blood Rev, 2019, 38: 100596. |
| [20] | Doan A, Pulsipher MA. Hypogammaglobulinemia due to CAR T-cell therapy[J]. Pediatr Blood Cancer, 2018, 65(4): 10.1002/pbc.26914. |
| [21] | Los-Arcos I, Iacoboni G, Aguilar-Guisado M, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper[J]. Infection, 2021, 49(2): 215-231. |
| [22] | Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells[J]. Biol Blood Marrow Transplant, 2020, 26(1): 26-33. |
| [23] | Bhella S, Majhail NS, Betcher J, et al. Choosing wisely BMT: American society for blood and marrow transplantation and Canadian blood and marrow transplant group's list of 5 tests and treatments to question in blood and marrow transplantation[J]. Biol Blood Marrow Transplant, 2018, 24(5): 909-913. |
| [24] | Dourthe ME, Rabian F, Yakouben K, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagen-lecleucel for B-cell acute lymphoblastic leukemia[J]. Leukemia, 2021, 35(12): 3383-3393. |
| [25] | Schultz LM, Eaton A, Baggott C, et al. Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia[J]. J Clin Oncol, 2023, 41(2): 354-363. |
| [26] | Jacoby E. The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia[J]. Bone Marrow Transplant, 2019, 54(Suppl 2): 810-814. |
| [27] | Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions[J]. J Allergy Clin Immunol Pract, 2022, 10(2): 460-466. |
| [28] | Gabelli M, Oporto Espuelas M, Bonney D, et al. ALL maintenance treatment for early loss of B-cell aplasia after tisagenlecleucel therapy[J]. Blood, 2021, 138(suppl 1): 3859. |
| [29] | Shiqi L, Jiasi Z, Lvzhe C, et al. Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T[J]. Mol Ther Oncolytics, 2023, 29: 107-117. |
| [30] | Holland EM, Molina JC, Dede K, et al. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation[J]. J Immunother Cancer, 2022, 10(5): e004483. |
/
| 〈 |
|
〉 |
